Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Rasmussen BB, et al. Among authors: thurlimann b. Lancet Oncol. 2008 Jan;9(1):23-8. doi: 10.1016/S1470-2045(07)70386-8. Epub 2007 Dec 20. Lancet Oncol. 2008. PMID: 18083065 Clinical Trial.
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A. Thürlimann B, et al. Breast Cancer Res Treat. 2004 Jun;85(3):247-54. doi: 10.1023/B:BREA.0000025420.78346.f9. Breast Cancer Res Treat. 2004. PMID: 15111763 Clinical Trial.
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni ME, Bernhard J, Siegrist HP, Schmitz SF, Gertsch MC, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C; Swiss Group for Clinical Cancer Research (SAKK). Sabbioni ME, et al. Among authors: thurlimann b. Breast Cancer Res Treat. 2004 Sep;87(1):75-86. doi: 10.1023/B:BREA.0000041584.53863.a7. Breast Cancer Res Treat. 2004. PMID: 15377853 Free article. Clinical Trial.
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Colleoni M, et al. Among authors: thurlimann b. J Clin Oncol. 2005 Mar 1;23(7):1390-400. doi: 10.1200/JCO.2005.06.052. J Clin Oncol. 2005. PMID: 15735115 Clinical Trial.
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Gruber G, et al. Among authors: thurlimann b. J Clin Oncol. 2005 Oct 1;23(28):7089-97. doi: 10.1200/JCO.2005.08.123. J Clin Oncol. 2005. PMID: 16192592 Clinical Trial.
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast International Group (BIG) 1-98 Collaborative Group; Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. Breast International Group (BIG) 1-98 Collaborative Group, et al. Among authors: thurlimann b. N Engl J Med. 2005 Dec 29;353(26):2747-57. doi: 10.1056/NEJMoa052258. N Engl J Med. 2005. PMID: 16382061 Free article. Clinical Trial.
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group Trial VIII. Bernhard J, et al. Among authors: thurlimann b. J Clin Oncol. 2007 Jan 20;25(3):263-70. doi: 10.1200/JCO.2005.04.5393. Epub 2006 Dec 11. J Clin Oncol. 2007. PMID: 17159194 Clinical Trial.
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Coates AS, et al. Among authors: thurlimann b. J Clin Oncol. 2007 Feb 10;25(5):486-92. doi: 10.1200/JCO.2006.08.8617. Epub 2007 Jan 2. J Clin Oncol. 2007. PMID: 17200148 Clinical Trial.
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. Karlsson P, et al. Among authors: thurlimann b. J Clin Oncol. 2007 May 20;25(15):2019-26. doi: 10.1200/JCO.2006.09.8152. Epub 2007 Apr 9. J Clin Oncol. 2007. PMID: 17420511
232 results